The receptor tyrosine kinase KIT and its ligand, stem cell factor (SCF), are essential for the proliferation and survival of normal melanocytes. In melanomas arising on mucosal, acral, and chronically sun-damaged skin, activating KIT mutations have been identified as oncogenic drivers and potent therapeutic targets. Through an initial whole-genome screen for aberrant promoter methylation in melanoma, we identified the KIT promoter as a target for hypermethylation in 43/110 melanoma cell lines, and in 3/12 primary and 11/29 metastatic cutaneous melanomas. Methylation density at the KIT promoter correlated inversely with promoter activity in vitro and in vivo, and the expression of KIT was restored after treatment with the demethylating agent 5-aza-2 0 -deoxycytidine. Hypermethylation of KIT showed no direct or inverse correlations with well-documented melanoma drivers. Growth of melanoma cells in the presence of SCF led to reduced KIT expression and increased methylation density at the KIT promoter, suggesting that SCF may exert a selection pressure for the loss of KIT. The frequent loss of KIT in cutaneous melanoma by promoter hypermethylation suggests that distinct KIT signaling pathways have opposing roles in the pathogenesis of melanoma subtypes.
INTRODUCTION
The growth, survival, migration, and differentiation of melanocytes are complex processes that are controlled by paracrine and autocrine cytokine networks (Imokawa, 2004) . One of the important paracrine growth factors for the melanocytic lineage is stem cell factor (SCF). During embryonic development, SCF is critical for the survival and proliferation of neural crest-derived melanoblasts, and it serves as guidance cues that direct the migration of these cells to their final destination in the hair follicle and epidermis (Lin and Fisher, 2007) .
Signal transduction by SCF occurs through KIT, a class III tyrosine kinase receptor that is expressed on several cell types, including hematopoietic progenitors, mast cells, melanoblasts, and differentiated melanocytes (Lennartsson and Rönnstrand, 2012) . Ligand binding causes KIT to homodimerize, leading to the activation of its intrinsic kinase activity through autophosphorylation of tyrosine residues. KIT has a number of potential tyrosine phosphorylation sites, which interact with multiple downstream signaling pathways, including the phosphatidylinositol 3-kinase, MAP kinase, and Src family kinase pathways (Lennartsson and Rönnstrand, 2012) . One of the downstream targets of these pathways is the melanocyte master regulator the microphthalmia transcription factor (MITF) (Levy et al., 2006) . Germline mutations in KIT, SCF, and MITF are associated with a range of pigmentation disorders (Lin and Fisher, 2007) , highlighting the importance of the KIT/SCF system and its signaling to MITF in controlling various cellular activities in the melanocytic system.
A large body of evidence has implicated aberrant KIT signaling in the development and progression of melanoma. Several studies based on immunohistochemical evaluation have shown that KIT is expressed in normal melanocytes and benign nevi, but it is lost with progression to invasive and metastatic forms (Montone et al., 1997; Shen et al., 2003; Zhu and Fitzpatrick, 2006) . Consistent with these data, KIT expression is lost in a great proportion of melanoma-derived cell lines (Lassam and Bickford, 1992; Natali et al., 1992; Zakut et al., 1993) , and lack of KIT expression correlates with a higher metastatic potential of melanoma xenografts in nude mice (Gutman et al., 1994) . Furthermore, forced KIT expression in KIT-deficient melanoma cell lines retards the growth of these cells in nude mice and confers susceptibility to SCF-induced growth arrest and apoptosis in vitro (Huang et al., 1996) . Although all of the above observations supported a tumor-suppressing role of KIT in melanoma, this view has markedly changed. Most importantly, genome-wide screens have uncovered KIT amplifications and activating mutations in a large proportion of melanomas on palms, soles and subungual sites (acral melanomas), mucosal membranes, and chronically sun-damaged skin (Curtin et al., 2006) . The See related commentary on pg 337 ORIGINAL ARTICLE 1 Danish Cancer Society Research Center, Copenhagen, Denmark and majority of KIT mutations occur in the juxtamembrane region of the receptor, which is also a target for mutations in 80% of gastrointestinal stromal tumors and smaller proportions of some hematological malignancies. These mutations lead to ligand-independent activation of KIT and its downstream signaling pathways (Lennartsson and Rönnstrand, 2012) , and they constitute potent therapeutic targets for the tyrosine kinase inhibitor imatinib mesylate, with clinical activity observed in patients with metastatic gastrointestinal stromal tumor (Heinrich et al., 2003) and in patients with metastatic KIT-mutated extracutaneous melanomas (Guo et al., 2011; Hodi et al., 2013) . Collectively, these later findings have established KIT as a bona fide oncogene in melanoma.
Research over the past 30 years has identified the main genetic drivers in cutaneous melanoma (reviewed in Dahl and Guldberg, 2007; Tsao et al., 2012) . In an effort to generate, on a whole-genome scale, a profile of epigenetic alterations in cutaneous melanoma, we initially compared promoter methylation patterns of four well-characterized melanoma cell lines with that of normal cultured melanocytes. This analysis led to the identification of KIT as a frequent target for epigenetic silencing in cutaneous melanoma.
RESULTS
Whole-genome promoter methylation profiling in melanoma cell lines and cultured melanocytes Genome-wide promoter methylation profiling was performed in normal cultured human epidermal melanocytes and four human melanoma cell lines (ESTDAB-019, ESTDAB-013, ESTDAB-024, and SK-MEL-28). We used the well-established methylated DNA immunoprecipitation (MeDIP) approach, which uses an anti-5-methylcytosine antibody to provide enrichment of DNA fragments containing 5-methylcytosine (Weber et al., 2005) . The enriched DNA was hybridized to human promoter microarrays containing 244 k 60-mer probes, which cover 5.5 kb upstream to 2.5 kb downstream of the transcription start site of B21,000 defined human RefSeqs. This approach allows unbiased analysis of gene promoters, including non-CpG island promoters, which can also be targets for silencing by DNA methylation in tumorigenesis (Han et al., 2011) . As our focus in this study was on DNA methylation changes with a potential impact on gene expression, we restricted our analysis to probes within proximal promoter regions, defined here as 300 nucleotides upstream and 200 nucleotides downstream of the transcription start site. Owing to the small sample size, we used M-values as the method for estimating methylation levels (Du et al., 2010) .
When comparing the methylation profile of normal melanocytes with those of melanoma cells, we identified 663 promoter regions that were hypermethylated in at least one of the four melanoma cell lines and 54 that were hypermethylated in all four cell lines (Supplementary Table S1 online). Examples of the array-based methylation profiling of these genes are shown in Figure 1a , illustrating the increased methylation levels around the transcription start site in melanoma cells compared with normal melanocytes. To validate the findings of the MeDIP analysis, we selected four genes for promoter methylation and gene expression analyses: DDIT4L, NID1, PPP1R3C, and RRAD. Two of these genes (DDIT4L and PPP1R3C) have previously been shown to be aberrantly hypermethylated in melanoma (Furuta et al., 2006; Koga et al., 2009; Gao et al., 2013) . The methylation status of each promoter was determined using methylation-sensitive melting-curve analysis (MS-MCA), which measures methylation content as a function of the melting temperature (T m ) of an amplicon generated from a bisulfite-treated template (Worm et al., 2001) . Analysis of DDIT4L, NID1, PPP1R3C, and RRAD confirmed the higher methylation levels in all four melanoma cell lines compared with normal melanocytes (Figure 1b and data not shown). Quantitative RT-PCR analysis of the same four genes revealed an inverse correlation between promoter hypermethylation and gene expression, with higher expression levels in melanocytes and low to undetectable expression in the cell lines (Figure 1c ).
KIT is frequently hypermethylated and silenced in melanoma cell lines
The KIT promoter was enriched in the MeDIP approach ( Figure 2a ; Supplementary Table S1 online) and was selected for more in-depth analysis. As shown in Figure 2b , ESTDAB-019 and SK-MEL-28 had an MS-MCA profile of the KIT promoter similar to that of the fully methylated control, melanocytes had a profile corresponding to the unmethylated control, and ESTDAB-013 and ESTDAB-024 had a composite profile. Bisulfite pyrosequencing confirmed that the KIT promoter was densely methylated in ESTDAB-019 and SK-MEL-28, unmethylated in melanocytes, and intermediately methylated in ESTDAB-013 and ESTDAB-024 ( Figure 2c and data not shown). Next, using MS-MCA, we determined the methylation status of the KIT promoter in 106 additional melanoma cell lines (Supplementary Table S2 online) . Overall, 43 of the 110 cell lines (39%) showed increased KIT promoter methylation levels.
Expression of KIT was analyzed in 70 of the 110 melanoma cell lines using RT-PCR (Supplementary Table S2 ; Fisher's exact test). However, the correlation was not absolute, as KIT mRNA was detected in 11 out of 50 cell lines with a hypermethylated KIT promoter (22%). To further characterize the association between methylation status and transcriptional activity of the KIT promoter, we determined the methylation density at 34 individual CpG sites using bisulfite pyrosequencing and measured expression levels using quantitative RT-PCR in 12 cell lines showing various MS-MCA profiles of KIT hypermethylation ( Figure 2d ). As shown in Figure 2e , KIT was expressed only in those three cell lines with the lowest KIT promoter methylation density (ESTDAB-013, EST146, and EST168). Furthermore, KIT expression was lost in all of the 14 cell lines with fully hypermethylated KIT promoters (Figure 2d and e, and data not shown), suggesting that methylation density at the KIT promoter is a main determinant of KIT expression.
To investigate a causal relationship between KIT promoter hypermethylation and transcriptional silencing, we treated four nonexpressing melanoma cell lines with the demethylating agent 5-aza-2 0 -deoxycytidine. RT-PCR analysis showed that 5-aza-2 0 -deoxycytidine restored KIT expression in a dosedependent manner ( Figure 2f and data not shown). Furthermore, FACS analysis showed that KIT was re-expressed at the cell surface in KIT-negative cells after treatment with 5-aza-2 0 -deoxycytidine ( Supplementary Fig S1b online) . Collectively, these results suggest that KIT promoter hypermethylation is a frequent cause of transcriptional silencing of KIT in melanoma cell lines. Loss of the transcription factor AP-2 has been suggested as a mechanism by which KIT expression is lost during melanoma progression (Huang et al., 1998) . However, AP-2 was expressed in all of the 27 melanoma cell lines tested, including 11 lacking KIT expression (data not shown).
KIT hypermethylation in uncultured melanomas
A previous study found KIT promoter hypermethylation in two rhabdomyosarcoma cell lines, which was considered as an in vitro artifact as aberrant KIT methylation was not detected in uncultured tumor specimens (Enguita-German et al., 2011) . To determine whether KIT promoter hypermethylation in melanoma cell lines was an in vitro culture phenomenon, we first took advantage of five frozen tumor biopsies from which some of our cell lines had been established. In all cases, cell line and corresponding tumor tissue had similar KIT promoter MS-MCA profiles. Most important, for the two cell lines with hypermethylated KIT (ESTDAB-019 and ESTDAB-023), large fractions of hypermethylated KIT alleles were detected in the corresponding uncultured specimens (Figure 3a and Supplementary Table S2 online), demonstrating that KIT hypermethylation had occurred in vivo.
We next investigated the methylation status of the KIT promoter region in frozen surgical biopsies from benign nevi (N ¼ 2) and primary (N ¼ 12) and metastatic (N ¼ 29) cutaneous melanomas using MS-MCA and confirmed the results for selected samples using bisulfite pyrosequencing (Figure 3b ). KIT promoter hypermethylation was detected in 3 of the primary melanomas (25%) and 11 of the metastatic melanomas (38%), and in none of the nevi (Supplementary  Table S3 ; Fisher's exact test).
Association of KIT promoter hypermethylation with known melanoma drivers Molecular cancer drivers often display patterns of mutual exclusivity across tumors, reflecting their partially redundant functions as individual components of the same oncogenic signaling pathways (Vogelstein and Kinzler, 2004) . To investigate whether KIT promoter hypermethylation was mutually exclusive to known melanoma drivers, we compared the KIT methylation status in 105 melanoma cell lines with the status of 15 common genetic (BRAF, NRAS, TP53, PTEN, INK4A (p16), ARF (p14), CCND1, MYC, CDK4, and MITF) and epigenetic (APC, IGFBP7, PYCARD, RARB, and RASSF1A) drivers, which have all been previously characterized in the same series of cell lines (Dahl et al., 2013) . KIT promoter hypermethylation showed direct correlations with other DNA methylation events, consistent with a CpG island methylator phenotype (Issa, 2004; Tanemura et al., 2009 ), but no statistically significant correlations with any of the genetic drivers (Supplementary Table S4 online).
Exposure to SCF triggers epigenetic silencing of KIT in melanoma cells
Previous work has shown that although SCF is required to support the proliferation and survival of normal melanocytic cells, it may inhibit the growth of KIT-expressing melanoma cells (Funasaka et al., 1992; Zakut et al., 1993) . Furthermore, Huang et al. (1996) showed that forced expression of KIT in the KIT-negative human melanoma cell line A375SM rendered these cells susceptible to SCF-induced cell-cycle arrest and apoptosis. To recapitulate these studies, but avoiding the possible confounding effects of KIT overexpression, we examined the effect of SCF on ESTDAB-013 melanoma cells, which express high levels of KIT and display a relatively low density of KIT promoter hypermethylation (Figure 2d and e) . We reasoned that these cells had a propensity to epigenetically silence KIT when a selection pressure was re-established. Initial FACS analysis showed that KIT was expressed on the surface of the vast majority of ESTDAB-013 cells (Figure 4a) . After 3 days of treatment with 200 ng ml À 1 SCF, there was no increase in the number of apoptotic cells, as determined by flow-cytometric analysis of annexin V levels (data not shown). However, after being cultured in the presence of SCF for 3 weeks, these cells showed reduced expression of KIT, as determined by FACS (Figure 4a ) and quantitative RT-PCR (Figure 4b ) analysis, as well as an increase in methylation density at the KIT promoter (Figure 4c and d) . These data suggest that SCF can induce epigenetic downregulation of KIT in melanoma cells in vitro.
DISCUSSION
Studies from various research disciplines have demonstrated an extensive heterogeneity of melanoma at the clinical, cellular, and molecular levels. Significant progress toward understanding this heterogeneity has been obtained through detailed genome-wide studies of somatic, genetic, and epigenetic alterations, which have uncovered distinct molecular profiles across melanoma stages and subtypes (Whiteman et al., 2011; Tsao et al., 2012) . One of the notable molecular differences lies within the profile of key driver oncogenes. Although BRAF and NRAS mutations are present in the majority of cutaneous and conjunctival melanomas, mutations in two members of the Ga q family of guanosine triphosphatases, GNAQ and GNA11, are common and mutually exclusive in uveal melanomas and blue nevi (Van Raamsdonk et al., 2010) , and KIT mutations are found nearly exclusively in melanomas arising on mucosal, acral, and chronically sun-damaged skin (Curtin et al., 2006) . The molecular background for this genetic variation remains unclear but may be related to differences in the inherent properties of precursor cells, differences in tissue microenvironment, or both (Whiteman et al., 2011) .
Given the well-established function of mutated KIT as a potent melanoma oncogene, the finding that this receptor is epigenetically silenced in a large proportion of cutaneous melanomas was unexpected. Specifically, we found that a CpG island in the promoter of KIT was hypermethylated in more than one-third of melanoma cell lines and biopsies. Furthermore, methylation density at this region correlated inversely with KIT expression in vitro and in vivo, and KIT expression could be restored by pharmacological DNA demethylation. Several mechanisms have been described that can mediate the downregulation of KIT, including dysregulated expression of specific microRNAs (Felicetti et al., 2008; Igoucheva and Alexeev, 2009; Siemens et al., 2013) or the AP-2 transcription factor (Huang et al., 1998) , consistent with the idea that loss of KIT is a consequence rather than a cause of melanoma progression. The frequent epigenetic silencing of KIT owing to promoter hypermethylation more directly implicates the loss of KIT in melanoma pathogenesis, substantiating previous suggestions that KIT may have a tumorsuppressive function in cutaneous melanoma. Furthermore, the strong correlation with transcriptional silencing suggests that KIT promoter hypermethylation represents the main mechanism responsible for stably inherited repression of KIT during melanoma progression.
The well-documented melanoma drivers display clear patterns of mutual exclusivity according to their functions in the canonical oncogenic signaling pathways (Dahl et al., 2013) . Epigenetic silencing of KIT did not correlate with any 
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Epigenetic Silencing of KIT in Cutaneous Melanoma of the known genetic melanoma drivers, suggesting that the tumor-suppressive role of KIT is associated with a hitherto unknown independent molecular pathway. Furthermore, as KIT is expressed in large proportions of metastatic melanomas and melanoma cell lines, it may not have a classical ''gatekeeper'' function in the context of cutaneous melanoma. The growth-suppressive function of KIT in some melanomas should probably best be viewed in the context of microenvironmental cues and intracellular signaling. Indeed, growth of KIT-expressing melanoma cells in the presence of SCF led to reduced KIT expression and increased methylation density at the KIT promoter, suggesting that SCF imposes a selection pressure for the loss of KIT. In this respect, our data support early studies showing that ectopic expression of KIT in melanoma cells sensitizes these cells to SCF (Huang et al., 1996) . In the adult skin, production of SCF by keratinocytes, endothelial cells, and fibroblasts is a main regulator of melanocyte homeostasis, supporting the recruitment, proliferation, and survival of melanocytes and their precursors (Grichnik, 2008; White and Zon, 2008) . The loss of requirement for ligand-dependent KIT activation during the transformation of melanocytic cells may at least in part be attributed to the redundant pathway activation through genetic modification, such as mutation of BRAF or NRAS. The mechanism conferring sensitivity of melanoma cells to SCF remains unknown, but it may be caused by a synthetic lethal relationship between SCF-induced and oncogenic signaling. It is known that growth-factor stimulation may have biphasic effects, with hyperstimulation of the RAS/MAPK pathway leading to cell cycle arrest, senescence, or death (Serrano et al., 1997) . Furthermore, as SCF-KIT interaction mediates melanocyte adhesion to keratinocytes and thereby prevents melanocyte proliferation (Haass and Herlyn, 2005) , there may be dual selection for melanocytes with an oncogenic mutation to lose KIT, both to escape from control by keratinocytes and to avoid overstimulation of the MAPK pathway.
The opposing functions of KIT in melanoma development, with growth-promoting effects in normal melanocytic cells and extracutaneous melanomas versus growth-suppressive effects in cutaneous melanomas, may have therapeutic implications. The identification of KIT as an oncogenic driver in extracutaneous melanomas (Curtin et al., 2006) has provided an important opportunity for targeted therapy of melanoma. However, clinical KIT inhibitors effectively target wild-type KIT, as demonstrated by skin hypopigmentation in patients treated with imatinib (Tsao et al., 2003) , and therefore could contribute to the progression of early-stage melanomas that are growth-inhibited owing to intrinsic expression of KIT. Therefore, caution should be taken against the use of KIT inhibitors for the treatment of melanomas of cutaneous origin or with unknown KIT status.
MATERIALS AND METHODS

Melanoma cell lines, melanocytes, and reagents
The 110 human melanoma cell lines used in this study (listed in Supplementary Table S2 online) have been described and characterized previously (Guldberg et al., 1997; Worm et al., 2004; Jönsson et al., 2007; Dahl et al., 2013) . The majority of these cell lines (N ¼ 105) were obtained from The European Searchable Tumour Line Database (ESTDAB) (http://www.ebi.ac.uk/ipd/estdab). SK-MEL-28 cells were purchased from the ATCC. Melanoma cells were routinely cultured as monolayers in RPMI 1640 medium containing 10% fetal bovine serum and antibiotics at 37 1C and 5% CO 2 . Primary human melanocytes (Invitrogen, Carlsbad, CA) were maintained in Medium 254 containing Human Melanocyte Growth Supplement 2 (Invitrogen) at 37 1C and 5% CO 2 . SCF and 5-aza-2 0 -deoxycytidine were purchased from Sigma-Aldrich (St. Louis, MO).
Pathologic specimens
Fresh-frozen biopsy specimens from benign nevi and melanomas were obtained from the Department of Pathology, Rigshospitalet, Copenhagen, Denmark (Worm et al., 2004) . The clinicopathological characteristics of these biopsies are listed in Supplementary Table S3 online. Formalin-fixed, paraffin-embedded sections from primary melanomas were obtained from the Institute of Pathology, Aarhus University Hospital, Aarhus, Denmark. All tumor samples were removed as part of the patient's treatment, and the study was approved by the local ethics committees. All tumor samples were removed as part of the patients' treatment, and only tissue sections that were not needed for diagnosis were used in the study. In accordance with Danish law and approval by the Danish Ethics Committee, patient consent was not required for the retrospective analysis of archival tissue biopsies.
DNA isolation and bisulfite treatment
Genomic DNA was isolated using the Qiagen Mini Prep kit (Qiagen GmbH, Hilden, Germany (cultured cells and fresh-frozen specimens)) or the Qiamp DNA FFPE Tissue Kit (Qiagen GmbH (formalin-fixed, paraffin-embedded sections)) and quantified using a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE). Bisulfite conversion of DNA was carried out using the EZ DNA Methylation-Goldt Kit (Zymo Research, Irvine, CA) according to the manufacturer's protocol.
MeDIP and microarray analysis
MeDIP assays were performed essentially as described (Weber et al., 2005) . Eight micrograms of genomic DNA extracted from melanoma cells and cultured epidermal melanocytes were sonicated using a Bioruptor (Diagenode, Liège, Belgium) to generate 200-to 600-bp fragments. Fragmented DNA (1.6 mg) was used as a reference sample, whereas the remaining was subjected to immunoprecipitation. DNA was denatured for 5 minutes at 95 1C and immunoprecipitated for 4 hours at 4 1C with 10 mg of monoclonal mouse antibody against 5-methylcytosine (Clone 33D3; 1 mg ml
; Eurogentec, Liège, Belgium) bound to pan-mouse IgG Dynal magnetic beads (Invitrogen). The efficiency of the MeDIP was evaluated by realtime quantitative PCR using previously validated targets (Dahl et al., 2013) . Primer sequences are listed in Supplementary Table S5 
MS-MCA and pyrosequencing
Methylation-specific melting curve analysis (MS-MCA) (Worm et al., 2001) was performed using the LightCycler 1.1 and 2.0 instruments (Roche) and the FastStart DNA Master SYBR Green I Kit (Roche).
Pyrosequencing was performed on a PyroMark Q24 platform, using PyroMark Gold Q24 Reagents (Qiagen, Valencia, CA). Data analysis was performed with the PyroMark Q24 software. Primer sequences are listed in Supplementary Table S5 online. Enzymatically methylated DNA (CpGenome Universal Methylated DNA; Millipore, Billerica, MA) was used as a methylation-positive control. DNA from peripheral blood leukocytes from a healthy donor and unmethylated DNA prepared by whole-genome amplification (WGA; GenomePlex, Sigma-Aldrich) were used as negative controls for methylation.
Reverse transcription PCR and quantitative reverse transcription PCR
Total RNA was isolated from melanoma cells and melanocytes using the RNeasy kit (Qiagen) and quantified using a Nanodrop spectrophotometer (Nanodrop Technologies). cDNA was synthesized from 2 mg of RNA using random hexamers, oligo-dT primers, and Superscript III Reverse Transcriptase (Invitrogen). Conventional PCR was carried out using a block thermocycler (GeneAmp PCR System 9600; Perkin-Elmer, Norwalk, CT) and the HotStar Taq DNA Polymerase (Qiagen). PCR products were analyzed in a 2% agarose gel. Real-time quantitative PCR was performed using the Roche LightCycler 2.0 and the FastStart DNA Master PLUS SYBR Green I Kit (Roche). Primer sequences are listed in Supplementary Table S5 online.
Immunohistochemistry
Immunohistochemistry was carried out on melanoma tissue microarrays, as described previously (Lade-Keller et al., 2013) . The sections were incubated at room temperature for 30 minutes with a primary antibody against KIT diluted 1:500 (polyclonal anti CD117 antibody, Dako, Glostrup, Denmark). Bound primary antibody was visualized using the Super Sensitive Polymer-HRP IHC kit (BioGenex, Fremont, CA) and a novared chromogen (Novared, Vector Laboratories, Petersborough, UK), and slides were counterstained with hematoxylin. All slides were digitalized using Zeiss Mirax Scan (Zeiss, Birkerd, Denmark) and evaluated on a computer screen using the Arrayimager software (Visiopharm, Hrsholm, Denmark). All tissue microarrays cores from each patient were evaluated together as a single sample. Positivity was defined as discrete staining with a predominantly membranous pattern. Internal positive control was basal cells and keratinocytes in normal epidermis. Negative internal control was normal keratinocytes in the outer layers of the epidermis. Liver tissue was used as an external negative control. The percentage of positively stained tumor cells was scored semiquantitatively and data were subsequently dichotomized into two groups: the KIT-negative group (0% tumor cells stained) and the KIT-positive group (40% tumor cells stained).
FACS analysis
Surface expression of KIT on melanoma cells was determined using a phycoerythrin-conjugated anti-KIT/CD117 antibody (AC126-PE; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and an isotype control antibody (PE Mouse IgG1 k Isotype Control; BD Biosciences, San Jose, CA). The cell samples were analyzed using an FC500 MPL Flow Cytometer (Beckman Coulter) and the CXP analytical software (Beckman Coulter, Brea, CA).
Apoptosis
Apoptosis was measured using the Annexin V-FITC Apoptosis Detection Kit (BD Biosciences). Cells were harvested and washed twice in cold phosphate-buffered saline and resuspended in binding buffer. A total of 5 Â 10 5 cells were stained with Annexin V-FITC and propidium iodide. After 30 minutes of incubation, the cell samples were analyzed using an FC500 MPL Flow Cytometer (Beckman Coulter).
Database accession
The array data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through the GEO Series accession number GSE53801 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53801).
